SYN-005-1B7 Biosimilar – Anti-Pertussis toxin subunit 1 mAb – Research Grade from ProteoGenix; catalogue PX-TA1918; research use only.
Know who made it. See the evidence. Buy through one marketplace.
SYN-005-1B7 Biosimilar is a monoclonal antibody (mAb) that specifically targets the pertussis toxin subunit 1 (PTxS1). This biosimilar is a research grade therapeutic antibody that has been developed as a potential treatment for pertussis, also known as whooping cough. In this article, we will discuss the structure, activity, and potential applications of SYN-005-1B7 Biosimilar.
SYN-005-1B7 Biosimilar is a recombinant humanized monoclonal antibody that is produced using advanced biotechnology techniques. It is a fully human IgG1 antibody that has been engineered to specifically bind to PTxS1, a key component of the pertussis toxin. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy and light chains are connected by disulfide bonds and form a Y-shaped structure that is characteristic of antibodies.
The primary function of SYN-005-1B7 Biosimilar is to bind to PTxS1 and inhibit its activity. PTxS1 is a key virulence factor of Bordetella pertussis, the bacterium that causes pertussis. This toxin is responsible for the severe coughing and other symptoms associated with the disease. By binding to PTxS1, SYN-005-1B7 Biosimilar prevents the toxin from entering and damaging the cells of the respiratory tract. This not only reduces the severity of symptoms but also helps in clearing the infection.
In addition to its neutralizing activity, SYN-005-1B7 Biosimilar also has an immune-modulating effect. It is able to stimulate the production of antibodies and T cells that specifically target B. pertussis. This helps in boosting the body’s immune response and provides long-term protection against pertussis.
The primary application of SYN-005-1B7 Biosimilar is in the treatment of pertussis. It is currently being developed as a potential alternative to the existing pertussis vaccines and antibiotics. The biosimilar is designed to be used as a passive immunization therapy, where it is administered to individuals who have been exposed to pertussis or are at high risk of developing the disease. This includes infants, pregnant women, and individuals with compromised immune systems.
Apart from its therapeutic potential, SYN-005-1B7 Biosimilar also has applications in research. The biosimilar can be used as a tool to study the mechanisms of pertussis infection and the role of PTxS1 in the disease. It can also be used to develop more effective vaccines and treatments for pertussis.
SYN-005-1B7 Biosimilar is a promising research grade therapeutic antibody that specifically targets PTxS1, a key virulence factor of B. pertussis. Its unique structure and activity make it a potential alternative to existing pertussis vaccines and antibiotics. The biosimilar has the potential to provide both immediate and long-term protection against pertussis and has applications in both therapeutic and research settings. Further studies and clinical trials are needed to fully evaluate the efficacy and safety of SYN-005-1B7 Biosimilar, but it holds great promise in the fight against pertussis.
ProteoGenix catalogue number PX-TA1918. For research use only.
Target: SYN-005-1B7 Biosimilar – Anti-Pertussis toxin subunit 1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| SYN-005-1B7 Biosimilar – Anti-Pertussis toxin subunit 1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
